State Street

State Street’s Evommune Inc EVMN Stock Holding History

State Street’s Portfolio EVMN Stock Details EVMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.13M	Buy	179,511 +148,011	+470%	+$3.35M	﹤0.01%	3038
2025 Q4	$539K	Buy	+31,500	New	+$592K	﹤0.01%	3659

Other funds holding EVMN

EQT Fund Management Luxembourg $1.02B AUM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Andera Partners Paris $206M AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street's EVMN Position: Q1 2026 in Review

State Street increased its Evommune Inc (EVMN) stake by 470% in Q1 2026, buying an estimated $3.35M and bringing the position to 179,511 shares worth $4.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

State Street first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

State Street held 179,511 shares of Evommune Inc worth $4.13M as of Q1 2026.
State Street bought 148,011 Evommune Inc shares in Q1 2026, an estimated $3.35M.
Evommune Inc made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3038 holding.
State Street first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.